Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BeiGene, Ltd.
  6. News
  7. Analyst Reco.
    BGNE   US07725L1026

BEIGENE, LTD.

(BGNE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Analyst Recommendations on BEIGENE, LTD.
05/09Morgan Stanley Lowers BeiGene's Price Target to $300 From $338, Maintains Overweight Ra..
MT
04/12Morgan Stanley Adjusts BeiGene's Price Target to $338 from $330, Keeps Overweight Ratin..
MT
03/17SVB Leerink Cuts BeiGene to Market Perform From Outperform, Price Target to $177 From $..
MT
03/01Nomura Upgrades BeiGene to Buy From Neutral, Adjusts Price Target to $310.62 From $293...
MT
03/01Nomura Upgrades BeiGene to Buy From Neutral, Adjusts Price Target to HK$186.85 From HK$..
MT
02/28Macquarie Lowers BeiGene's Price Target to $301.60 From $312.80, Maintains Outperform R..
MT
02/28Morgan Stanley Lowers BeiGene's Price Target to $330 From $360, Maintains Overweight Ra..
MT
02/28Goldman Sachs Lowers BeiGene's Price Target to $364.32 From $410.60, Maintains Buy Rati..
MT
02/28SVB Leerink Adjusts BeiGene's Price Target to $300 from $334, Maintains Outperform Rati..
MT
01/18Morgan Stanley Adjusts BeiGene's Price Target to $360 from $407, Keeps Overweight Ratin..
MT
2021Nomura Adjusts BeiGene's Price Target to $293.28 From $355.83, Maintains Neutral Rating
MT
2021Nomura Adjusts Beigene's Price Target to HK$176.97 From HK$214.05, Keeps at Neutral
MT
2021Nomura Adjusts BeiGene to Neutral From Not Rated, Sets $355.83 Price Target
MT
2021BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf..
MT
2021BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target
MT
2021BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $407 From $409, Maintains Over..
MT
2021BEIGENE : SVB Leerink Adjusts BeiGene's Price Target to $417 from $388, Keeps Outperform R..
MT
2021BEIGENE : Morgan Stanley Adjusts Price Target on BeiGene to $409 From $357, Maintains Over..
MT
2021BEIGENE : Morgan Stanley Adjusts BeiGene's Price Target to $357 from $375, Keeps Overweigh..
MT
2021BEIGENE : HSBC Adjusts BeiGene's Price Target to $385 from $296, Keeps Buy Rating
MT
2021BEIGENE : China Renaissance Initiates Coverage on BeiGene With Buy Rating
MT
2021BEIGENE : CLSA Downgrades BeiGene to Underperform From Outperform, Adjusts Price Target to..
MT
2021BEIGENE : Cowen & Co. Adjusts Price Target on BeiGene to $429 From $348, Maintains Outperf..
MT
2021BEIGENE : Morgan Stanley Adjusts BeiGene PT to $375 From $310, Maintains Overweight Rating
MT
2020BEIGENE : Ladenburg Thalmann Upgrades BeiGene to Buy From Neutral; Price Target is $278
MT
2020BEIGENE : SVB Leerink Adjusts BeiGene's Price Target to $327 From $240, Keeps at Outperfor..
MT
2020BEIGENE : Morgan Stanley Adjusts BeiGene PT to $310 From $270, Maintains Overweight Rating
MT
2020BEIGENE : Ladenburg Thalmann Downgrades BeiGene to Neutral from Buy
MT
2020BEIGENE : Piper Sandler Downgrades BeiGene to Underweight From Neutral; Price Target is $1..
MT
Analysis
Exclusive - Chinese regulators ask some U.S.-listed firms to prepare for audit disclosures - sources
Upcoming event on BEIGENE, LTD.
06/03/22AMERICAN SOCIETY FOR CLINICAL ONCOLOGY MEETING - ABSTRACT NUMBER: e16095
Upcoming sector events
07/27/22VERTEX PHARMACEUTICALS INCORPORATED : Interim 2022 Earnings Release (Projected)
07/27/22GILEAD SCIENCES, INC. : Interim 2022 Earnings Release (Projected)
08/04/22REGENERON PHARMACEUTICALS, INC. : Interim 2022 Earnings Release (Projected)
08/08/22BIONTECH SE : Interim 2022 Earnings Release
Sector
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs